Combined GLP-1 Receptor Agonist and SGLT2 Inhibitor Therapy Improves Cardiovascular and Kidney Outcomes in Patients with Advanced Chronic Kidney Disease: A Real-World Cohort Study

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

Presented the abstract " "
(Abstract co-author(s): )

Back

E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.

E-Poster Format Requirements

PDF file
Layout: Portrait (vertical orientation)
One page only (Dim A4: 210 x 297mm or PPT)
E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
File Size: Maximum file size is 2 Megabytes (2 MB)
No hyperlinks, animated images, animations, and slide transitions
Language: English
Include your abstract number
E-posters can include QR codes, tables and photos

E-Poster

Abstract Title *

Combined GLP-1 Receptor Agonist and SGLT2 Inhibitor Therapy Improves Cardiovascular and Kidney Outcomes in Patients with Advanced Chronic Kidney Disease: A Real-World Cohort Study

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

The title will not be accepted if it exceeds 25 words.
Type in CAPITAL LETTERS.
Lowercase may be used for abbreviations only, for example, mRNA.

Co-author 1

Chih-Chin Kao 121008@h.tmu.edu.tw Taipei Medical University Hospital Internal Medicine Taipei Taiwan *

Co-author 2

Yen-Chung Lin yclin0229@tmu.edu.tw Taipei Medical University Hospital Internal Medicine Taipei Taiwan -

Co-author 3

I-Wen Wu fliawu@yahoo.com Taipei Medical University Hospital Internal Medicine Taipei Taiwan -

Co-author 4

Sheng-Feng Lin linshengfeng@tmu.edu.tw Taipei Medical University Hospital Emergency Medicine Taipei Taiwan -

Co-author 5

Co-author 6

Co-author 7

Co-author 8

Co-author 9

Co-author 10

Co-author 11

Co-author 12

Co-author 13

Co-author 14

Co-author 15

Introduction

Patients with chronic kidney disease (CKD) face markedly increased risks of cardiovascular events and mortality. Recent studies have demonstrated the benefits of glucagon-like peptide-1 receptor agonists (GLP1-RA) in individuals with diabetes and CKD. However, whether the combination of GLP1-RA and sodium-glucose cotransporter-2 inhibitors (SGLT2i) provides additional benefits compared with SGLT2i alone in advanced CKD remains unclear.

Methods

We conducted a retrospective cohort study using the TriNetX Research Network to identify adults with CKD stage 4–5 or on dialysis between January 1, 2005, and April 1, 2024. Patients were divided into two groups: (1) combined GLP1-RA and SGLT2i therapy and (2) SGLT2i monotherapy. Propensity score matching was applied to balance baseline characteristics, and patients were followed for up to 12 months. The primary outcome was major adverse cardiovascular events (MACE), defined as cardiovascular death, stroke, myocardial infarction, or all-cause mortality. Secondary outcomes included kidney events, myocardial infarction, and ischemic stroke.

Results

Among 71,961 eligible patients (22,769 receiving combination therapy; 49,192 receiving SGLT2i alone), 21,941 matched pairs were analyzed. At 12 months, combination therapy was associated with lower risks of MACE (HR 0.872; 95% CI 0.840–0.904) and kidney outcomes (HR 0.868; 95% CI 0.819–0.919). Reduced risks of myocardial infarction (HR 0.888; 95% CI 0.836–0.944) and all-cause mortality (HR 0.654; 95% CI 0.612–0.698) were also observed, while no significant difference in ischemic stroke was noted (HR 1.040; 95% CI 0.988–1.096).

Conclusion

In patients with advanced CKD, the combination of GLP1-RA and SGLT2i was associated with improved cardiovascular and kidney outcomes compared with SGLT2i alone. These findings support the potential synergistic benefits of dual therapy in this high-risk population.

Kewords